● In Stock

BPC-157 / TB500

🧪 ≥99% Purity | HPLC Verified
$80.00
🔒 Secure Checkout
🔬 Third-Party Tested
✓ Money-Back Guarantee
PASSED Sterility & Endotoxins
PASSED Net Content & Purity
🧪 Purity: ≥99%
❄️ Store at -20°C

BPC-157 and TB-500 research stack studied for synergistic tissue repair and accelerated recovery. Research use only.

Strength 20mg
Purity >99% (HPLC)
Form Lyophilized Powder
📚
370+
Combined Studies
200+ BPC-157 · 170+ TB-500 citations
⬆️
7x
GHR Upregulation
BPC-157 in tendon tissue (day 3)
🩹
61%
Faster Healing
TB-500 re-epithelialization at 7 days
🛡️
No LD50
Toxicity
Neither peptide reached lethal dose
Dual-Pathway Synergy

How the Wolverine Stack Works

Two complementary peptides — BPC-157 builds blood supply, TB-500 moves cells to the site

VEGF
VEGFR2 Pathway BPC-157
Vascular Endothelial Growth Factor Receptor 2
  • Promotes new blood vessel formation (angiogenesis)
  • Increases blood flow to injured areas
  • Activates endothelial cell proliferation
Actin
G-Actin Sequestration TB-500
Monomeric Globular Actin Binding · Cell Migration
  • Regulates cytoskeletal remodeling
  • Facilitates cell motility and migration
  • Enables wound closure mechanisms
ILK
ILK/Akt Pathway TB-500
Integrin-Linked Kinase Complex · Cell Survival
  • Promotes cell survival signaling
  • Activates Akt pathway
  • Supports cardiac and muscle cell migration
Why They Work Together
Complementary Regenerative Pathways
BPC-157 promotes blood vessel formation through VEGFR2-Akt-eNOS signaling. TB-500 promotes cell migration by regulating actin dynamics. Both reduce inflammation — creating optimal healing conditions from multiple angles.
BPC-157 primary actionAngiogenesis (VEGF) ✓
TB-500 primary actionCell Migration (Actin) ✓
Shared effectAnti-inflammatory
Combined resultComprehensive repair
GlobalRPH Clinical Review, 2025
BPC-157 Component
VEGFR2-Akt-eNOS Signaling
BPC-157 activates the VEGFR2 pathway, triggering the Akt-eNOS cascade. This increases nitric oxide production and promotes new blood vessel formation at injury sites — ensuring adequate nutrient and oxygen delivery to healing tissue.
  • VEGFR2 upregulation + receptor internalization
  • Akt-eNOS cascade activation
  • 7× GHR upregulation in tendon (day 3)
  • Blood flow recovery in ischemic tissue
  • No lethal dose established (preclinical)
Research Evidence

What Research Has Shown

Preclinical evidence from individual peptide studies — 370+ combined publications

2
Distinct but Complementary Regenerative Pathways
VEGFR2 angiogenesis (BPC-157) + Actin/ILK cell migration (TB-500) — synergy inferred from complementary mechanisms
Individual Component Efficacy
TB-500: Keratinocyte migration+200%
BPC-157: Tendon outgrowth+85%
BPC-157: Cell migration+70%
TB-500: Re-epithelialization (7d)+61%
Tissue Healing by Component
TB-500: Wound closure−61%
BPC-157: Tendon healing−50%
BPC-157: Muscle repair−40%
TB-500: Neuro recovery+35%
Safety Profile (Combined)
TB-500 trial completion rate100%
TB-500 serious adverse events0
BPC-157 LD50 reachedNever
7x
GHR Upregulation (BPC-157)
Day 3 in tendon tissue
0
SAEs (TB-500 Phase 1)
42–1,260mg IV, 14 days
370+
Combined Publications
200+ BPC-157 · 170+ TB-500
Research Applications

Why Researchers Study This Combination

Complementary mechanisms targeting multiple aspects of tissue repair

Tendon & Ligament
Connective Tissue
BPC-157 fibroblast outgrowth + TB-500 cell migration address both vascular supply and cellular repair in connective tissue.
  • BPC-157: +85% tendon fibroblast outgrowth
  • TB-500: +200% keratinocyte migration
  • Combined: vascular + cellular repair
  • Most studied application for the stack
Wound Healing
Skin Repair
TB-500 accelerates re-epithelialization 61% while BPC-157 promotes angiogenesis to supply the wound bed with nutrients and oxygen.
  • TB-500: 61% faster wound closure (7d)
  • BPC-157: New vessel formation to wound
  • Both: Anti-inflammatory modulation
  • Complementary coverage of wound healing phases
Muscle Recovery
Skeletal Muscle
FAK/paxillin signaling (BPC-157) combined with actin regulation (TB-500) targets both signaling and structural aspects of muscle repair.
  • BPC-157: FAK/paxillin pathway activation
  • TB-500: Actin cytoskeletal remodeling
  • BPC-157: ~40% faster muscle repair
  • Cardiovascular benefit: ILK activation
Anti-Inflammatory
Dual Control
Both peptides independently modulate NF-κB signaling and inflammatory cytokines — providing overlapping but distinct anti-inflammatory coverage.
  • BPC-157: NF-κB modulation confirmed
  • TB-500: Toll-like receptor pathway regulation
  • Both: Pro-resolving pathway activation
  • No immunosuppression — targeted modulation
Compound Specifications

BPC-157 vs TB-500

Individual component profiles and blend information

15 Amino AcidsGastric Origin1,419.5 g/mol
BPC-157
Body Protection Compound-157
TypeSynthetic pentadecapeptide
CAS Number137525-51-0
Molecular weight1,419.5 g/mol
Amino acids15
SequenceGEPPPGKPADDAGLV
OriginHuman gastric juice
43 Amino AcidsThymus Origin4,963 Da
TB-500
Thymosin Beta-4 (Fragment)
TypeSynthetic / endogenous peptide
CAS Number77591-33-4
Molecular weight4,963 Da
Amino acids43
Active region17LKKTET22 (actin binding)
OriginThymus, platelets
Dual pathwaysResearch only
Blend Information
Why "Wolverine Stack"?
BPC-157 mechanismVEGFR2 / Angiogenesis
TB-500 mechanismActin / Cell migration
Common overlapAnti-inflammatory
WADA statusBanned (S0, since 2022)
Scientific Literature

Key Publications

Selected research from 370+ combined BPC-157 and TB-500 publications

Common Questions

Frequently Asked Questions

Common questions about the Wolverine Stack

The name references the Marvel character Wolverine, known for his rapid healing abilities. BPC-157 and TB-500 are two regenerative peptides that work through different but complementary pathways — BPC-157 promotes blood vessel formation (angiogenesis) while TB-500 enhances cell migration. Together, they address multiple aspects of tissue repair, leading to the nickname "Wolverine blend" in research circles.

No formal clinical trials have been published specifically on the combination. The synergistic potential is inferred from their complementary mechanisms and independent efficacy data. BPC-157 has over 200 preclinical studies, while TB-500 has completed Phase 1 and Phase 2 (dry eye) trials. Both demonstrate convergent effects on angiogenesis and inflammation through distinct molecular targets.

BPC-157 primarily works through the VEGFR2-Akt-eNOS pathway to promote angiogenesis (blood vessel formation), while TB-500 primarily works through G-actin sequestration to promote cell migration and cytoskeletal remodeling. For tissue repair, both are needed: blood vessels to supply nutrients and oxygen, and cells that can migrate to the injury site. Both peptides also independently modulate inflammatory pathways.

Both peptides individually show favorable safety profiles. BPC-157 has no established lethal dose (LD50) in preclinical studies with no organ toxicity detected. TB-500 Phase 1 trials showed no serious adverse events at IV doses up to 1,260mg daily for 14 days. However, no combination safety studies exist, and both peptides promote angiogenesis — which theoretically could affect tumor growth. Neither peptide is FDA approved.

Neither BPC-157 nor TB-500 is FDA approved for human therapeutic use. Both are banned by WADA (World Anti-Doping Agency) under category S0 (non-approved substances) since 2022, and BPC-157 is on the DoD Prohibited Dietary Supplement list. They may be available for research purposes through some channels, but this does not imply safety or efficacy for human use.

Both peptides have been administered via subcutaneous injection, intramuscular injection, intravenous infusion, and orally in research settings. BPC-157 is notably stable in gastric juice for over 24 hours, supporting oral administration. TB-500 Phase 1 trials used IV administration. There are no established combination protocols — researchers typically derive dosing from individual peptide studies.

BPC-157 (15 amino acids, MW 1,419.5 g/mol) is derived from gastric juice and works primarily through VEGFR2-mediated angiogenesis and growth hormone receptor upregulation. TB-500 (43 amino acids, MW 4,963 Da) is derived from the thymus and platelets and works primarily through G-actin sequestration to drive cell migration. Think of BPC-157 as building the road (blood supply) and TB-500 as driving the repair crew (cell migration) to the injury site.

Published research on this compound is available through PubMed and other scientific databases.

Search PubMed →

Certificate of Analysis

Analysis Date: Available on request
Lot Number: Batch-specific
Purity: >99% (HPLC)

Third-Party Testing

  • ✓ Identity verification (Mass Spectrometry)
  • ✓ Purity analysis (HPLC)
  • ✓ Sterility testing
  • ✓ Endotoxin screening

Storage Conditions

  • Lyophilized: Store at -20°C, protected from light
  • Reconstituted: Store at 2-8°C, use within 30 days
  • Stability: 24 months from manufacture date when stored properly

Handling Guidelines

  • Use sterile technique when reconstituting
  • Allow vial to reach room temperature before opening
  • Reconstitute with bacteriostatic water or sterile saline
  • Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
🔬
3D Structure

BPC-157 / TB500

This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.

  • • High-purity research compound
  • • Full analytical documentation included
  • • Third-party verification available
ℹ️ PRODUCT SPECIFICATIONS

LOT DATA

Lot Number ✓ Assigned on shipment
Verified Purity ✓ >99%
Quantity ✓ 5mg

MOLECULAR DATA

Molecular Formula Available on request
Form Lyophilized Powder
Appearance White to off-white powder

Researchers who studied this also studied...

Related products

⚠️

These products are intended for laboratory research purposes only, and are not for human or animal consumption.

For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. All products sold by Eon Peptides are intended strictly for laboratory research and analytical purposes by qualified professionals. These materials are not approved for any therapeutic, diagnostic, or medical application.